Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

Gut

Volumn 59, Issue 9, 2010, Pages 1265-1269

  McPherson, Stuart ^a   Stewart, Stephen F ^a   Henderson, Elsbeth ^a   Burt, Alastair D ^b   Day, Christopher P ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; AST ALT RATIO; AST TO PLATELET RATIO INDEX; BARD SCORE; BODY MASS; DIAGNOSTIC ACCURACY; FEMALE; FIB 4 SCORE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NAFLD FIBROSIS SCORE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; BIOPSY; BLOOD; COMPLICATION; EPIDEMIOLOGY; FATTY LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; EPIDEMIOLOGIC METHODS; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 77956119396     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.216077     Document Type: Article

References (29)

1. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-17. (Pubitemid 30044177)
2. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
3. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-14.
4. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;124:375-7.
5. Teli MR, James OF, Burt AD, et al. The natural history of non alcoholic fatty liver: a follow up study. Hepatology 1995;22:1714-19.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
7. Matteoni CA, Younossi ZM, Gramlich T, et al. Non alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-19. (Pubitemid 29258890)
8. Fassio E, Alvarez E, Dominguez N, et al. Natural history of non alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6.
9. Ekstedt M, Franzen LE, Mathiesen UL, et al. Longterm follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
10. Argo CK, Northup PG, Al-Osaimi AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9.
11. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.
12. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in non alcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7.
13. Al Knawy B, Shiffman M. Percutaneous liver biopsy in clinical practice. Liver Int 2007;27:1166-73. (Pubitemid 47543144)
14. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
15. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
16. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
17. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-9.
18. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7.
19. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6.
20. Angulo P, Hui J, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:847-54.
21. ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27: S5-10.
22. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
23. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104-12.
24. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-60.
25. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.
26. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-62.
27. 2. J Hepatol 2009;50:S359.
28. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006;6:34. (Pubitemid 44848812)
29. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-78.